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Abstract 
Purpose: Age is a poor prognostic factor in melanoma patients. Elderly melanoma patients 
have a different presentation and clinical course than younger patients. We evaluated the 
impact of age ≥70 years (yrs) on the diagnosis and natural history of melanoma. 
Methods: Retrospective review of 610 patients with malignant melanoma entered into a 
prospective sentinel lymph node (SLN) database, treated from June 1997 to June 2010. 
Disease characteristics and clinical outcomes were compared between patients ≥70 yrs vs. 
<70 yrs of age.  
Results: 237 patients (39%) were ≥70 yrs. Elderly patients had a higher proportion of head 
and neck melanomas (34% vs. 20%, p<0.001), and greater mean tumor thickness (2.4mm vs. 
1.8mm, p<0.001). A greater proportion of T3 or T4 melanoma was seen in the elderly 
(p<0.001) as well as a greater mean number of mitotic figures: 3.6/mm
2 vs. 2.7/mm
2 (p=0.005). 
Despite greater mean thickness, the incidence of SLN metastases was less in the ≥70 yrs 
group with T3/T4 melanomas (18% vs. 33%, p=0.02). The elderly had a higher rate of local and 
in-transit recurrences, 14.5% vs. 3.4% at 5 yrs (p<0.001). 5 yr disease-specific mortality and 
overall mortality were worse for those ≥70 yrs: 16% vs. 8% (p=0.004), and 30% vs. 12% 
(p<0.001), respectively.  
Conclusions: Elderly (≥70 yrs) melanoma patients present with thicker melanomas and a 
higher mitotic rate but have fewer SLN metastases. Melanoma in the elderly is more common 
on the head and neck. Higher incidence of local/in-transit metastases is seen among the el-
derly. Five-year disease-specific mortality and overall mortality are both worse for these pa-
tients. 
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Introduction 
The incidence of malignant melanoma has been 
increasing over the last several decades. Melanoma is 
the  sixth  most  common  malignancy  in  the  United 
States; there were an estimated 68,120 new cases of 
invasive melanoma in 2010 with 8,700 deaths due to 
the  disease  1,  2.  When  compared  to  younger  age 
groups, mortality is significantly higher in the elderly 
implicating age as a poor prognostic factor  3. As the 
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proportion of the elderly among the world population 
continues to grow3, nearing 20% in developed coun-
tries4, so will the importance of melanoma character-
ization and proper risk stratification in that age group.  
The clinical presentation and pathological char-
acteristics in melanoma of the elderly differ from that 
of  their  younger  counterparts.  Melanoma  of  the  el-
derly has been shown to be more common in men and 
to be discovered later in its development. The inci-
dence of ulceration, high mitotic index, and advanced 
Breslow thickness have been shown to be higher in 
older  age  groups5-8.  Paradoxically,  despite  lower 
overall survival in elderly with malignant melanoma, 
the rate of positive sentinel lymph nodes (SLN) de-
creases with age3, 9-11. This observation remains unex-
plained but is likely related at least in part to atrophy 
of skin lymphatics that occur with age12. 
Given the differing clinical presentation, patho-
logical characteristics, and heightened mortality rates 
of elderly melanoma patients, we aimed to compare 
disease  characteristics  and  clinical  outcomes  of  pa-
tients 70 years of age and older versus under 70 years 
old. 
Methods 
We reviewed 610 patients with malignant mel-
anoma requiring SLN biopsy entered into a prospec-
tive SLN database from Mayo Clinic Arizona, treated 
from June 1997 to June 2010. Approval was obtained 
from the Institutional Review Board. Disease charac-
teristics  and  clinical  outcomes  were  compared  be-
tween  patients  ≥70  yrs  vs.  <70  yrs  of  age.  Subset 
analysis was performed with a breakdown between 
age groups of <50, 50-59, 60-69 and >70, but the sta-
tistical power of this analysis was limited due to the 
smaller  number  of  events  in  the  groups.  Primary 
melanoma  anatomic  locations  were  divided  in  four 
locations: head and neck, lower extremity, trunk, and 
upper extremity. Characteristics of the primary mel-
anoma that were analyzed included: Breslow’s depth, 
T-stage  (<1mm,  1-2mm,  2.01-4mm,  >4mm),  ulcera-
tion, tumor infiltrating lymphocytes (TIL), preexisting 
nevus, angiolymphatic invasion, perineural invasion, 
and  mitotic  rate.  Regional  disease  was  assessed  by 
SLN  biopsy  results.  Disease  outcome  measures  in-
cluded type of recurrence (local/in-transit, regional, 
systemic), time to recurrence, time to local/in-transit 
recurrence,  disease-specific  mortality,  and  overall 
mortality.  
Categorical  variables  were  compared  between 
groups using chi-squared tests. Continuous variables 
were  compared  between  groups  using  two-sample 
independent samples t-tests. Disease outcomes were 
plotted  using  Kaplan-Meier  curves  and  compared 
between  groups  using  Cox  proportional  hazards 
models. Statistical software used included SAS soft-
ware, version 9 (SAS Institute). P-values <0.05 were 
considered statistically significant throughout.  
Results 
237  (39%)  patients  with  melanoma  requiring 
SLN biopsy were ≥70 years. The mean age in the <70 
years old group was 52.2 (14-69). Among the elderly 
group (≥70 yrs), the mean age was 77.3 (70-97), there 
was a greater predominance of men, 153 (65%) com-
pare  to  those  <  70  yrs,  where  men  comprised  56% 
(p=0.04), Table 1. The location of melanomas was sig-
nificantly different between the elderly and younger 
patients (p<0.001). The elderly patients had a higher 
proportion of head and neck melanomas (34%) rela-
tive to the younger patients (19%), whose most prev-
alent site was the trunk (35%). 
Comparison  of  disease  characteristics  between 
age groups appears in Table 1.  
 
Table 1: Patient and Melanoma Characteristics by Age 
Group. 
Primary tumor charac-
teristics 
<70 yrs  ≥70 yrs  Total 
Male  56%  65%  59% 
Location 
 Head and Neck 
 Trunk 
 Upper Extremity 
 Lower Extremity 
 
20% 
35% 
21% 
24% 
 
34% 
23% 
22% 
22% 
 
25% 
30% 
21% 
23% 
Pre-existing Nevus  36%  17%  29% 
Mean Breslow Level 
(SD) 
1.8 (1.5)  2.4 (2.5)  2.0 (1.9) 
T Stage 
 T1 
 T2 
 T3 
 T4 
 
33% 
43% 
15% 
8% 
 
19% 
39% 
31% 
12% 
 
28% 
41% 
21% 
9% 
Tumor Infiltrating 
Lymphocytes 
 Absent 
 Non-brisk 
 Brisk 
 
34% 
46% 
21% 
 
32% 
50% 
18% 
 
33% 
47% 
20% 
Ulceration  23%  29%  26% 
Angiolymphatic or Per-
ineural Invasion 
11%  15%  13% 
Mean Mitotic Figure 
Rate [per mm2] (SD) 
2.7 (3.0)  3.6 (4.2)  3.0 (3.5) 
SLN+  
 Entire cohort 
 T1/2 
 T3/4 
 
15% 
9% 
33% 
 
11% 
6% 
18% 
 
13% 
 
SD = standard deviation 
 
 
Elderly patients had thicker tumors, with 43% of 
elderly patients had a T3 or T4 melanoma compared 
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≥70  had  a  greater  mean  number  of  mitotic  figures, 
3.6/mm2  vs.  2.7/mm2  (p=0.005)  including  a  greater 
preponderance  of  lesions  with  a  high  mitotic  rate 
>5/mm2 (29% vs 17%, p=0.003. The elderly patients 
did not have a greater prevalence of ulceration. Tu-
mors in the elderly were less likely to arise from a 
pre-existing nevus, 17% vs. 36% (p=0.003). There were 
no differences in tumor infiltrating lymphocyte status 
or angiolymphatic invasion.  
Overall, the prevalence of SLN metastases was 
similar  between  elderly  and  non-elderly  patients. 
When the incidence of SLN metastases was stratified 
by  T  stage  (T1/T2  and  T3/T4),  the  rate  of  positive 
SLNs  was  dramatically  less  common  in  elderly  pa-
tients with T3 or T4 melanoma versus their younger 
counterparts (18% vs. 33%, p=0.02). 
The median follow up time was 3.8 years (range 
0-12.6 years). The elderly patients had a higher rate of 
recurrence  (including  local/in-transit,  regional,  or 
systemic recurrence) relative to the younger patients 
(25.2%  vs  9.1%  5  years  after  surgery;  hazard  ratio 
[HR]=2.6,  p<0.001;  Figure  1A).  Additionally,  the  el-
derly  patients  had  a  higher  rate  of  local/in-transit 
recurrence  (14.5%  vs  3.4%  5  years  after  surgery; 
HR=3.6, p<0.001; Figure 1B) and systemic recurrence 
(14.9% vs 6% 5 years after surgery; HR=1.83, p=0.05; 
figure 1C).  
Subset analysis of age groups <50, 50-59, 60-69 
and >70 showed progressively worse outcomes with 
age, as expected. Recurrence-free survival rates in the 
subset analysis were 91.8%, 85.6%, 82%, and 60% re-
spectively for age groups in ascending order. Relative 
to age  group <50, hazard ratios for the age groups 
50-59, 60-69, and >70 were 1.98 (p=0.08), 2.15 (p=0.03), 
and 5.42 (p<0.001) respectively.  
5-year mortality rate from all causes was greater 
in  the  elderly  group,  29.8%  vs.  12.3%  5  years  after 
surgery (HR=3.0, p<0.001; Figure 2A). Additionally, 
5-year disease-specific mortality was higher for those 
≥70 years old: 16.1% vs. 8.2% (HR=2.3, p=0.004; Figure 
2B).  In  a  multivariate  model  of  melanoma-specific 
survival, age remained significant after adjusting for 
known  prognostic  factors  of  tumor  thickness  and 
positive SLN status. 
Discussion 
In our cohort of patients undergoing SLN biop-
sy, melanoma in the elderly was more common on the 
head and neck, less likely to arise from a pre-existing 
nevus, had greater mean tumor thickness and more 
mitotic  figures  than  melanoma  in  their  younger 
counterparts. Additionally, higher T-stage melanoma 
in the elderly was less likely to result in positive sen-
tinel  node  biopsy.  Furthermore,  elderly  melanoma 
patients had worse outcomes. They were more likely 
to  have  recurrence,  including  a  higher  rate  of  lo-
cal/in-transit  recurrence  and  systemic  recurrence. 
Consequently,  they  had  a  higher  disease-specific 
mortality and worse overall survival. 
 
           
 
 
 
 
 
Figure 1: Kaplan-Meier Plots of Time to Recurrence (A), 
Time  to  Local/In-Transit  Recurrence  (B),  and  Time  to 
Systemic Recurrence (C).  Journal of Cancer 2011, 2 
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Figure 2: Kaplan-Meier Plots of Overall Survival (A) and 
Disease-Specific Survival (B). 
 
 
Older age is recognized as an independent poor 
prognostic factor in melanoma patients. Caraco et al. 
studied 399 patients with melanoma who underwent 
SLN biopsy and compared patients <50 years vs. >50 
years. They found the melanoma patients >50 to have 
thicker  lesions  and  a  higher  incidence  of  ulceration 
but no difference in the incidence of lymph node me-
tastases. Overall survival was worse among the group 
>50 and age was a significant prognostic variable in 
multivariate analysis13. Data from the SEER database 
and  Medicare  enrollment  and  claims  files,  showed 
that increasing age after 65 years and melanoma de-
tection by a dermatologist were significantly predic-
tive of survival on multivariate analysis in a popula-
tion  of  over  2000  patients  14.  In  a  large  dataset  of 
17,600  melanoma  patients,  age  was an  independent 
prognostic factor for overall survival which was con-
sistent  within  each  thickness  subgroup9.  Worse 
prognosis in the elderly may be attributable to the fact 
that the elderly, especially elderly men, melanoma has 
been  shown  to  have  a  more  rapid  growth  rate15, 
thicker tumors16 and histologic ulceration16. Age as a 
poor prognostic factor may be the result of weakened 
immune defense mechanisms 17, 18, which may play a 
role  in  melanoma  progression.  Lastly,  competing 
co-morbidities are much more prevalent in older pa-
tients, further contributing to higher overall mortality. 
Elderly melanoma patients have been shown to 
present with tumors of advanced Breslow level 3, 9, 19, 
20. Late diagnosis has been implicated as a cause for 
thicker melanoma with poor prognosis in the elderly. 
Multiple factors are likely involved in late discovery 
of cutaneous malignancies in the elderly. Some rea-
sons may include scarcely visible anatomical locations 
of new pigmented lesions (i.e. scalp, back), loss of a 
partner’s  input  on  home  examination,  poor  vision, 
less importance placed on changing lesions, and con-
fusing new or changing benign seborrheic keratoses 
for pigmented lesions21, 22. Furthermore, early detec-
tion programs for melanoma have generally targeted 
younger age groups. Studies have shown dispropor-
tionately  low  screening  of  elderly  men  despite  this 
population  accounting  for  44%  of  melanoma  cases 
discovered23.  
Higher incidence of head and neck melanoma is 
likely  attributable  to  cumulative  photodamage  and 
higher incidence of lentigo maligna melanoma as pa-
tients age. Swetter et al. showed that lentigo maligna 
melanoma was the only melanoma subtype with in-
creasing  incidence  over  a  ten-year  period  and  was 
more common in men ≥65 years 24. As the percentage 
of elderly persons in the world’s population continues 
to grow, physicians performing melanoma screening 
should  devote  heightened  attention  to  heavily 
sun-exposed sites where melanoma is more and more 
commonly discovered. 
Our  data  confirmed  previously  reported  find-
ings that the elderly are less likely to have melanoma 
associated  with  a  pre-existing  nevus25.  Malignant 
progression may be the result of continuous and cu-
mulative photodamage to melanocytes not within a 
nevus26. This has clinical implications to patient edu-
cation and early detection of melanoma in that age 
group.  When  counseling  elderly  patients  regarding 
self-screening, a shift of focus from characteristics of 
changing nevi (ABCDE of melanoma) to awareness of 
any new growths may lead to more routine screening 
and earlier detection. 
Our data demonstrated that the mitotic rate in 
the elderly melanoma patients was higher than their 
younger counterparts. Mitotic rate has been associat-
ed with worse clinical outcomes in melanoma patients 
and has been identified as an independent prognostic 
factor  in  multiple  studies  27-29.  In  a  multifactorial 
analysis  of  10,233  patients  with  clinically  localized 
melanoma, mitotic rate was the second best prognos-
tic factor of survival behind tumor thickness  29. In a  Journal of Cancer 2011, 2 
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series of more than 1200 cases, mitotic rate was sig-
nificantly  associated  with  survival  and  more  prog-
nostic  than  tumor  ulceration  28.  Higher  mitotic  rate 
tumor  burden  has  also  been  implicated  as  a  factor 
contributing to a greater likelihood of local/in-transit 
recurrence and poor clinical outcomes 30. Paek et al. 
showed mitotic rate is associated with positive SLN, 
but the impact of mitotic activity on SLN result was 
less  in  the  elderly  compared  to  younger  cohorts  31. 
Our data was consistent  with  these  observations as 
our  elderly  population  had  more  mitotic  figures, 
greater  number  of  non-regional  recurrences,  and 
worse  clinical  outcomes.  Additionally,  they  had  a 
lower positive SLN rate, indicating that mitotic activ-
ity had less impact on SLN result in the elderly com-
pared to younger patients.  
In  advanced  T-stage  melanoma,  despite  worse 
disease-specific and overall mortality, the elderly had 
far fewer cases of positive SLN biopsies. This paradox 
is consistent with evidence from prior studies  3, 9-11. 
Chao et al. studied 5 age groups of melanoma patients 
in a large series of over 3000 patients. They showed a 
progressive  decline  in  incidence  of  SLN  metastasis 
with  increasing  age  across  all  five  age  groups.  The 
oldest group (>60 years) had a positive SLN rate of 
14.4%,  significantly  less  than  the  next  nearest  age 
groups  3. Our cohort of elderly patients (≥70 years) 
demonstrated a comparable rate of positive SLN in 
11%. 
The reason for fewer cases of positive sentinel 
lymph node biopsies remains uncertain but may be 
accounted  by  altered  lymphatic  drainage  in  the  el-
derly12. Although the mode of spread in any cancer is 
never  certain,  it  appears  that  like  younger  patients, 
melanoma  in  the  elderly  principally  spreads  along 
lymphatic routes as there are more in-transit metas-
tases noted in this age group  32. UV irradiation has 
been shown to induce VEGF-A-mediated damage of 
cutaneous lymphatic channels 33, 34. Lifelong accumu-
lation of photodamage is likely contributory to dis-
ruption  of  lymphatic  channels,  as  well  as  gravi-
ty-dependent  degeneration,  disallowing  complete 
migration of tumor cells to the sentinel node in areas 
of atrophied lymphatic channels in the elderly.  
Older  age  in  this  study  was  associated  with 
shorter  time  to  recurrence.  Time  to  recurrence  has 
been  shown  to  be  an  independent  predictor  of 
post-recurrence  survival35.  Additionally,  advanced 
age at the time of recurrence diagnosis has been asso-
ciated with poor prognosis 36-38. Murali et al. studied 
279  melanoma  patients  with  recurrence  and  found 
that those patients who had recurrence in 12 months 
or less from treatment of primary melanoma had sig-
nificantly  worse  post-recurrence  survival  and  pro-
gression-free survival rates35. A recent long-term fol-
low-up study of 2487 patients showed that advanced 
age, male sex, high pN, and distant metastases as the 
first  site  of  recurrence  were  associated  with  worse 
survival outcomes after the manifestation of recurrent 
disease38.  
This study has limitations. The analysis relied on 
data obtained from a single institution. Subset analy-
sis of age groups <50, 50-59, 60-69, >70 was of limited 
statistical power because of small number of events in 
each  group.  Data  was  retrieved  only  from  patients 
undergoing  sentinel  lymph  node  biopsy;  given  the 
potential selection bias, it may not be valid to gener-
alize conclusions to the entire elderly population with 
melanoma. Lastly, the follow-up period is limited to a 
mean of 3.8 years, which may influence outcome data 
to reflect more poorly on the elderly population. 
Given the differing clinical presentation, primary 
melanoma  characteristics,  and  disparate  dis-
ease-specific  outcomes  of  melanoma  in  the  elderly 
compared to non-elderly patients, clinicians and sur-
geons  should  be  mindful  of  proper  screening  and 
risk-stratification of elderly patients when participat-
ing in their care. Due to the higher risk of in-transit 
disease, follow-up should focus on loco-regional re-
currences. These clinical differences may have signif-
icant  implications  for  clinical  trials.  Many  adjuvant 
clinical trials are geared to patients with lymph node 
positive disease. Due to the fact that the elderly have a 
much lower incidence of lymph node positive disease 
but otherwise poorer prognosis, age may need to be 
included when developing clinical trials in order to 
evaluate the efficacy of adjuvant therapy in this pa-
tient population. 
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